Literature DB >> 12655524

Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method.

Hee Jung An1, Nam Hoon Cho, Sun Young Lee, In Ho Kim, Chan Lee, Seung Jo Kim, Mi Sook Mun, Se Hyun Kim, Jeongmi Kim Jeong.   

Abstract

BACKGROUND: Human papillomavirus (HPV) infection is considered to play an important role in the development of cervical carcinoma, and it is known that certain HPV types, such as HPV-16 and HPV-18, are highly associated with cervical carcinoma. However, the pathologic behavior of other HPV types remains unclear. Recently, a new HPV detection technique, the HPV DNA chip, was introduced. The HPV DNA chip harbors 22 HPV probes and has the advantage of being able to detect 22 HPV types simultaneously. To evaluate the quality of the HPV DNA chip method and to identify HPV types related to cervical carcinoma and precancerous lesions, the authors performed HPV typing in cervical specimens from 1983 patients and compared their cytologic and histologic diagnoses.
METHODS: The HPV DNA chip was used for HPV typing. Among 1983 patients who were tested for HPV types, cervical smear cytology was performed in 1650 patients, and 677 of those patients underwent cervical biopsy.
RESULTS: Among the 1650 smears that were examined cytologically, 92.7% (114 of 123 smears) of low-grade squamous intraepithelial lesions (LSILs), 98.1% (106 of 108 smears) of high-grade squamous intraepithelial lesions (HSILs), and 96.3% (51 of 53 smears) of carcinomas were HPV positive, compared with only 35.1% of smears with normal cytology that were HPV positive. HPV-16 was the most prevalent type (chi-square test; P < 0.01) in LSILs (28.5%), in HSILs (51.9%), and in carcinomas (62.5%) followed by HPV-58 and a group of low-risk types (HPV-6, HPV-11, HPV-34, HPV-40, HPV-42, HPV-43,and HPV-44) in LSILs. HPV-58 (15.7%), HPV-18 (6.7%), and HPV-52 (4.6%) were the next most prevalent types after HPV-16 in HSILs. HPV-18 (11.4%) and HPV-58 (11.4%) were the second most common types in carcinomas. HPV-58 had the highest positive predictive value (54.9%) for the detection of histologically confirmed HSIL or carcinoma, whereas HPV 16 had the highest negative predictive value (80.6%). The sensitivity (96.0%) of the HPV test using the DNA chip method for detecting HSIL or carcinoma was superior compared with the sensitivity of cytologic diagnosis (83.6%).
CONCLUSIONS: The HPV DNA chip provides a very sensitive method for detecting 22 HPV genotypes with reasonable sensitivity (96.0%) and reasonable negative predictive value (96.9%), and it overcomes the low sensitivity of cytologic screening for the detection of HSIL or carcinoma. HPV-58, HPV-52, and HPV-56, as well as HPV-16 and HPV-18, were associated highly with HSIL and carcinoma in the current large series. In addition, multiple HPV infection was associated less frequently with cervical carcinoma and with precancerous lesions compared with normal cytology. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11235

Entities:  

Mesh:

Year:  2003        PMID: 12655524     DOI: 10.1002/cncr.11235

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Epidemiology and genotype distribution of high risk human papillomavirus in population of hospital opportunistic screening.

Authors:  Ying-Qiao Liu; Xin He; Sha-Sha Xu; Jiu-Xin Qu; Yue Wang; Xiao-Li Diao; Jun Liu; Shu-Zhen Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses.

Authors:  Tae Jeong Oh; Chang Jin Kim; Suk Kyung Woo; Tae Seung Kim; Dong Jun Jeong; Myung Soon Kim; Sunwoo Lee; Hyun Sill Cho; Sungwhan An
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

3.  Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study.

Authors:  Jing Ye; Xiaodong Cheng; Xiaojing Chen; Feng Ye; Weiguo Lü; Xing Xie
Journal:  Virol J       Date:  2010-03-23       Impact factor: 4.099

4.  Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women.

Authors:  Agnihotram V Ramanakumar; Otelinda Goncalves; Harriet Richardson; Pierre Tellier; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  BMC Infect Dis       Date:  2010-11-11       Impact factor: 3.090

5.  Performance of a polymer-based DNA chip platform in detection and genotyping of human papillomavirus in clinical samples.

Authors:  T Schenk; T Brandstetter; A Zur Hausen; J Alt-Mörbe; D Huzly; J Rühe
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

6.  Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses.

Authors:  Nicole Kessler; Olivier Ferraris; Kevin Palmer; Wayne Marsh; Adam Steel
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

7.  DNA microarray format for detection and subtyping of human papillomavirus.

Authors:  Corné H W Klaassen; Clemens F M Prinsen; Hanneke A de Valk; Alphons M Horrevorts; Marcel A F Jeunink; Frederik B J M Thunnissen
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 8.  Cutaneous squamous cell carcinoma and human papillomavirus: is there an association?

Authors:  Bishr Aldabagh; Jorge Gil C Angeles; Adela R Cardones; Sarah T Arron
Journal:  Dermatol Surg       Date:  2012-08-28       Impact factor: 3.398

9.  Current status of cervical cancer and HPV infection in Korea.

Authors:  Young-Tak Kim
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

10.  HPV-Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia.

Authors:  Oscar Peralta-Zaragoza; Jessica Deas; Claudia Gómez-Cerón; Wendy Argelia García-Suastegui; Geny Del Socorro Fierros-Zárate; Nadia Judith Jacobo-Herrera
Journal:  Obstet Gynecol Int       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.